Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06638151
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-04
Brief Title:
Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy andor Intravenous Thrombolysis CoPrime
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy andor Intravenous Thrombolysis CoPrime A Randomized Pilot Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CoPrime
Brief Summary:
Stroke is a common cause of disability The most common type of stroke an ischemic stroke is caused by a blood vessel in the brain getting blocked by a clot When this happens part of the brain is damaged because it is not getting the blood supply it needs To treat this type of stroke doctors give medication andor do a procedure to remove the blockage and restore blood supply to the brain
Unfortunately patients who have had an ischemic stroke are at higher risk of having another ischemic stroke This risk is highest in the first 21 days after a stroke Currently doctors give patients the medication aspirin every day starting 24 hours after stroke treatment to prevent recurrent strokes However some studies have shown that giving another medication clopidogrel in addition to aspirin is safe and may work better than aspirin alone at preventing repeat strokes Both aspirin and clopidogrel are a type of medication called an antiplatelet that prevents clots from forming in the blood When both medications are given together it is called dual antiplatelet treatment The main risk of antiplatelet medications is bleeding
This research aims to study the safety and feasibility of using dual antiplatelet treatment to prevent recurrent strokes Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding Following informed consent patients at low risk of bleeding will be enrolled in the study 24 hours after their initial stroke treatment Patients will be randomly assigned to either take aspirin alone or aspirin and clopidogrel for 21 days for recurrent stroke prevention The study team will then follow patients for three months after treatment to collect information about their recovery and assess differences between the two groups
Unfortunately patients who have had an ischemic stroke are at higher risk of having another ischemic stroke This risk is highest in the first 21 days after a stroke Currently doctors give patients the medication aspirin every day starting 24 hours after stroke treatment to prevent recurrent strokes However some studies have shown that giving another medication clopidogrel in addition to aspirin is safe and may work better than aspirin alone at preventing repeat strokes Both aspirin and clopidogrel are a type of medication called an antiplatelet that prevents clots from forming in the blood When both medications are given together it is called dual antiplatelet treatment The main risk of antiplatelet medications is bleeding
This research aims to study the safety and feasibility of using dual antiplatelet treatment to prevent recurrent strokes Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding Following informed consent patients at low risk of bleeding will be enrolled in the study 24 hours after their initial stroke treatment Patients will be randomly assigned to either take aspirin alone or aspirin and clopidogrel for 21 days for recurrent stroke prevention The study team will then follow patients for three months after treatment to collect information about their recovery and assess differences between the two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None